Padeliporfin VTP for Peripheral Lung Cancer
This study is testing a new treatment called Padeliporfin Vascular Targeted Photodynamic (VTP) therapy for people with peripheral lung tumors. This therapy uses a robotic-assisted bronchoscopy (a procedure where a thin tube is inserted into the airways) to deliver Padeliporfin, a special drug, directly to the tumor. Then, a laser light is used to activate the drug. The main goals of this study are to check the safety and how well this treatment can be performed. Researchers also want to find the best light dose to use. You might be able to join if you are 18 or older and have a primary lung lesion with a high risk of being lung cancer, and surgery is planned.
- Study design
- This is a Phase 1/1b, open-label study designed to assess safety and feasibility, and to find the right light dose. It plans to enroll 36 participants.
- What's involved
- You would undergo a robotic-assisted bronchoscopy with Padeliporfin VTP treatment under general anesthesia. Surgery will be performed 5 to 21 days after the VTP procedure.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will measure safety at Day 30 and evaluate the maximum tolerated light dose by Day 14 after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Lonny Yarmus, MD · PRINCIPAL_INVESTIGATOR · Johns Hopkins University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety of robotic assisted bronchoscopic Padeliporfin VTP ablationDay 30
Incidence of treatment-related adverse events as assessed by CTCAE v5.0
- Feasibility of robotic assisted bronchoscopic Padeliporfin VTP treatmentDay 1
Feasibility of robotic bronchoscopic light fiber delivery into the target lesion as confirmed by cone beam CT and complete VTP treatment
- Evaluate Maximum Tolerated light Dose and/or RP2D of Padeliporfin VTP ablationDay 14
Evaluate Maximum Tolerated light Dose and/or RP2D of robotic assisted bronchoscopic Padeliporfin VTP ablation (a vascular targeted photodynamic therapy with Padeliporfin of patients with peripheral stage 1A1/1A2) primary non-small cell lung cancers.